EGFR and lung cancer: The research project described in this protocol will provide important new information about the everyday impacts, both beneficial and harmful, arising from the introduction of erlotinib and gefitinib into routine clinical use for treating advanced EGFR mutation–positive lung cancer in NZ a little more than 1 decade ago.